logo-loader
viewEmerald Bioscience Inc.

Emerald Bioscience gearing up for first in-human clinical trial in Australia to treat glaucoma

Emerald Bioscience Inc (OTCMKTS:EMBI) CEO Brian Murphy spoke with Proactive’s Steve Darling at the 12th annual LD Micro Conference in Bel Air, California, about the medical cannabis company’s proprietary suite of technologies, including its lead product candidate that could reduce intraocular pressure.

Emerald Bioscience gearing up for first in-human clinical trial in Australia. 

Quick facts: Emerald Bioscience Inc.

Price: 0.148 USD

OTCQB:EMBI
Market: OTCQB
Market Cap: $19.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Phunware reveals details for upcoming Phun Ecosystem launch mid-2020

Phunware Inc (NASDAQ:PHUN) Product and Engineering EVP Matt Lindenberger tells Proactive the technology company has unveiled a litany of milestones for 2019 as well as a roadmap detailing its plans for the commercial launch of its Phun Ecosystem this year. Lindenberger says the company is very...

1 hour, 50 minutes ago

2 min read